Share this Page:
There is limited information on the outcomes of patients who are treated with an immunotherapy combination as a first-line treatment followed by a tyrosine kinase inhibitor (TKI) as a second-line treatment for advanced kidney cancer.
A recent study looked at data from 105 patients who stopped first-line treatment with an immunotherapy combination. Some then went on to have a second line treatment with a TKI. Patient outcomes were compared between patients who were treated with a combination of two immunotherapies (e.g., ipilimumab plus nivolumab) and those who were treated with a combination of immunotherapy and TKI as their first-line treatment.
This study, which used real-world data from the clinic, showed that outcomes (in particular the time to when the treatment stopped working and the cancer started growing again, called progression-free survival) were better in patients treated with a combination of immunotherapies as a first-line treatment, compared to those treated with an immunotherapy-TKI combination as a first-line treatment.
